Evaluation of Sulfonamide Detoxification Pathways in Haematologic Malignancy Patients Prior to Intermittent Trimethoprim-sulfamethoxazole Prophylaxis

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2011 Jan 6

PMID 21204907

Citations 4

Authors

Mahmoud Abouraya

James C Sacco

Brad S Kahl

Lauren A Trepanier

Affiliations

Soon will be listed here.

Abstract

Aims: Patients with haematologic malignancies have a reportedly high incidence of sulfamethoxazole (SMX) hypersensitivity. The objective of this study was to determine whether deficiencies in sulfonamide detoxification pathways, to include glutathione (GSH) and ascorbate (AA), and cytochrome b(5) (b5) and cytochrome b(5) reductase (b5R), were prevalent in these patients. A secondary pilot objective was to determine whether the incidence of drug hypersensitivity following intermittent trimethoprim-SMX (TMP-SMX) prophylaxis approached that reported for high dose daily regimens.

Methods: Forty adult patients with haematologic malignancies (HM) and 35 healthy adults were studied; an additional 13 HM patients taking ascorbate supplements (HM-AA) were also evaluated. Twenty-two of 40 HM patients were prescribed and were compliant with TMP-SMX 960 mg three to four times weekly.

Results: There were no significant differences between HM and healthy groups in plasma AA (median 37.2 µm vs. 33.9 µm) or red blood cell GSH (1.9 mmvs. 1.8 mm). However, plasma AA was correlated significantly with leucocyte b5/b5R reduction (r= 0.39, P= 0.002). Deficient b5/b5R activities were not found in HM patients. In fact, patients with chronic lymphocytic leukaemia or myeloma had significantly higher median activities (80.7 µmol mg(-1) min(-1)) than controls (18.9 µmol mg(-1) min(-1), P= 0.008). After 3-4 weeks of treatment, no patients developed SMX-specific T cells and only one patient developed rash.

Conclusions: Deficiencies of blood antioxidants and b5/b5R reduction were not found in this population with haematologic malignancies, and the development of skin rash and drug-specific T cells appeared to be uncommon with intermittent TMP-SMX prophylaxis.

Citing Articles

Antibiotic prophylaxis in immunosuppressed patients - Missed opportunities from trimethoprim-sulfamethoxazole allergy label.

Lee W, Lam L, Bacchi S, Jiang M, Inglis J, Smith W World Allergy Organ J. 2024; 17(1):100856.

PMID: 38235260 PMC: 10793173. DOI: 10.1016/j.waojou.2023.100856.

Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection.

Wong Y, Rakasz E, Gasper D, Friedrich T, Trepanier L Toxicology. 2016; 368-369:10-18.

PMID: 27565715 PMC: 5069186. DOI: 10.1016/j.tox.2016.08.010.

CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer.

Woischke C, Blaj C, Schmidt E, Lamprecht S, Engel J, Hermeking H Oncotarget. 2016; 7(21):31350-60.

PMID: 27120783 PMC: 5058761. DOI: 10.18632/oncotarget.8912.

Short- and long-term cure rates of short-duration trimethoprim-sulfamethoxazole treatment in female dogs with uncomplicated bacterial cystitis.

Clare S, Hartmann F, Jooss M, Bachar E, Wong Y, Trepanier L J Vet Intern Med. 2014; 28(3):818-26.

PMID: 24673608 PMC: 4895459. DOI: 10.1111/jvim.12324.

References

Arruda V, Salles T, Costa F, Saad S . Glutathione peroxidase, reduced glutathione, superoxide dismutase and catalase in red cells of patients with hairy cell leukemia. Neoplasma. 1996; 43(2):99-102. View

Reghis A, Troungos C, Lostanlen D, Krishnamoorthy R, Kaplan J . Characterization of weak alleles at the DIA1 locus (Mustapha 1, Mustapha 2, and Mustapha 3) in the Algerian population. Hum Genet. 1983; 64(2):173-5. DOI: 10.1007/BF00327119. View

Verhagen C, Stalpers L, De Pauw B, Haanen C . Drug-induced skin reactions in patients with acute non-lymphocytic leukaemia. Eur J Haematol. 1987; 38(3):225-30. DOI: 10.1111/j.1600-0609.1987.tb01168.x. View

Mansouri A, Nandy I . NADH-methemoglobin reductase (cytochrome b5 reductase) levels in two groups of American blacks and whites. J Investig Med. 1998; 46(2):82-6. View

Williams S, MacDonald P, Hoyer J, Barr R, Athale U . Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatr Blood Cancer. 2004; 44(1):55-62. DOI: 10.1002/pbc.20164. View

Lavergne S, Wang H, Callan H, Park B, Naisbitt D . "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J Pharmacol Exp Ther. 2009; 331(2):372-81. PMC: 2775259. DOI: 10.1124/jpet.109.155374. View

Khoo B, Leow Y . A review of inpatients with adverse drug reactions to allopurinol. Singapore Med J. 2000; 41(4):156-60. View

Rieder M, Uetrecht J, Shear N, Cannon M, Miller M, Spielberg S . Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med. 1989; 110(4):286-9. DOI: 10.7326/0003-4819-110-4-286. View

Davis C, Shearer W . Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol. 2008; 121(4):826-832.e5. DOI: 10.1016/j.jaci.2007.10.021. View

10.

Uetrecht J . Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2006; 47:513-39. DOI: 10.1146/annurev.pharmtox.47.120505.105150. View

11.

Naisbitt D, Farrell J, Gordon S, Maggs J, Burkhart C, Pichler W . Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol. 2002; 62(3):628-37. DOI: 10.1124/mol.62.3.628. View

12.

Neuman M, Malkiewicz I, Phillips E, Rachlis A, Ong D, Yeung E . Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit. 2002; 24(6):728-36. DOI: 10.1097/00007691-200212000-00008. View

13.

Hughes W, Rivera G, Schell M, Thornton D, Lott L . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987; 316(26):1627-32. DOI: 10.1056/NEJM198706253162604. View

14.

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

15.

Bhusari S, Abouraya M, Padilla M, Pinkerton M, Drescher N, Sacco J . Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine. Arch Toxicol. 2010; 84(8):597-607. PMC: 2910208. DOI: 10.1007/s00204-010-0530-z. View

16.

Kurian J, Bajad S, Miller J, Chin N, Trepanier L . NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther. 2004; 311(3):1171-8. DOI: 10.1124/jpet.104.072389. View

17.

Bakan N, Taysi S, Yilmaz O, Bakan E, Kuskay S, Uzun N . Glutathione peroxidase, glutathione reductase, Cu-Zn superoxide dismutase activities, glutathione, nitric oxide, and malondialdehyde concentrations in serum of patients with chronic lymphocytic leukemia. Clin Chim Acta. 2003; 338(1-2):143-9. DOI: 10.1016/j.cccn.2003.08.013. View

18.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

19.

Trepanier L, Yoder A, Bajad S, Beckwith M, Bellehumeur J, Graziano F . Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole-nitroso in HIV infection. J Acquir Immune Defic Syndr. 2004; 36(5):1041-50. DOI: 10.1097/00126334-200408150-00007. View

20.

Lavergne S, Kurian J, Bajad S, Maki J, Yoder A, Guzinski M . Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Toxicology. 2006; 222(1-2):25-36. DOI: 10.1016/j.tox.2006.01.018. View